Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug...
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease May 28, 2026 Download PDF Share Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3)
Explore this link on the map →saved by
related reading
- Eliglustat - Wikipediaen.wikipedia.org
- New Genzyme pill will cost patients $310,250 a year - The Boston Globeweb.archive.org
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- The roles of glycosphingolipids in the proliferation and neural differentiation of mouse embryonic stem cells - PMCpmc.ncbi.nlm.nih.gov
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- UpToDateuptodate.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- Research Areas - Svendsen Lab | Cedars-Sinaicedars-sinai.edu
- Huntington's disease successfully treated for first timebbc.com
- UpToDateuptodate.com
- The Frontier in 2025renaissancephilanthropy.org